Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2016-11-30

FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for ZEMPLAR (paricalcitol) to update labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zemplar (Paricalcitol)

Snippet

SUPPL AP for ZEMPLAR (PARICALCITOL)